

## HR 7845

NIH Clinical Trial Diversity Act of 2022

**Congress:** 117 (2021–2023, Ended)

**Chamber:** House

**Policy Area:** Health

**Introduced:** May 19, 2022

**Current Status:** Referred to the Subcommittee on Health.

**Latest Action:** Referred to the Subcommittee on Health. (May 20, 2022)

**Official Text:** <https://www.congress.gov/bill/117th-congress/house-bill/7845>

### Sponsor

**Name:** Rep. Kelly, Robin L. [D-IL-2]

**Party:** Democratic • **State:** IL • **Chamber:** House

### Cosponsors (4 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Butterfield, G. K. [D-NC-1]	D · NC		May 19, 2022
Rep. Cárdenas, Tony [D-CA-29]	D · CA		May 19, 2022
Rep. Clarke, Yvette D. [D-NY-9]	D · NY		May 19, 2022
Rep. Fitzpatrick, Brian K. [R-PA-1]	R · PA		May 19, 2022

### Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred to	May 20, 2022

### Subjects & Policy Tags

**Policy Area:**

Health

### Related Bills

Bill	Relationship	Last Action
117 S 4486	Related bill	<b>Jun 23, 2022:</b> Read twice and referred to the Committee on Finance.

## NIH Clinical Trial Diversity Act of 2022

This bill sets out requirements to increase the diversity of clinical trial participants. The bill also requires other activities to foster participation in clinical trials.

As a condition of funding from the National Institutes of Health (NIH) for a clinical trial investigating a drug or device, a sponsor's application must include certain information related to diversity in its trial, such as

- goals for recruiting and retaining trial participants,
- plans for achieving the recruitment and retention goals and implementing less-burdensome clinical trial follow-up requirements, and
- education and training requirements related to diversity in clinical trials for researchers and other individuals who conduct or support the trial.

A sponsor must also annually share demographic data of clinical trial participants with the NIH. The NIH must publish on its website information about the diversity of and other information concerning the clinical trials it funds.

If a sponsor fails to meet its goals or other requirements with respect to trial diversity, the sponsor must develop and implement a strategic plan to increase the diversity of the clinical trial participants.

Further, the NIH and the Food and Drug Administration must carry out a national campaign to increase awareness about the need for diverse clinical trials.

The bill also requires studies on barriers to participation in clinical trials. The Government Accountability Office must study actions taken by federal agencies to address such barriers while the NIH must study regulations that govern reimbursements of out-of-pocket expenses of and incentives for clinical trial participants.

## Actions Timeline

---

- **May 20, 2022:** Referred to the Subcommittee on Health.
- **May 19, 2022:** Introduced in House
- **May 19, 2022:** Referred to the House Committee on Energy and Commerce.